Aquestive Therapeutics Reports Third-Quarter 2026 Financial Results and Business Update
Story updates
09:02:04 PM UTC
SquawkNews
Aquestive Therapeutics 3Q Loss $16.5M >AQST
09:02:04 PM UTC
SquawkNews
Aquestive Therapeutics 3Q Rev $7.56M >AQST
09:02:06 PM UTC
SquawkNews
Aquestive Therapeutics 3Q Loss/Shr 13c >AQST
09:03:14 PM UTC
SquawkNews
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first an
09:23:00 PM UTC
SquawkNews
Aquestive Therapeutics reported third-quarter 2026 revenue of $7.6M, down 41% from $12.8M a year earlier, as manufacture and supply revenue declined. Net loss was $16.5M, compared with a $15.4M loss in the prior-year quarter, while diluted EPS was $(0.13), versus $(0.14).Financial HighlightsBusines…